THE CORRELATIONS BETWEEN CYTOKINE PARAMETERS OF IMMUNE INFLAMMATION, ENDOTHELIAL GROWTH FACTOR AND BIOCHEMICAL PARAMETERS IN PATIENTS WITH GOUT
L.V. Natrus, D.V. Maltsev, Yu.G. Klys, T.I. Panova, V.E. Kondratiuk, S.E.Konovalov
Bogomoletz National Medical University, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz66.05.055
![](/images/cite.png)
Abstract
The correlations between cytokine status, vascular endothelial
growth factor (VEGF) content, clinical and biochemical parameters in patients with various forms of gout were studied
to improve the algorithm for monitoring of clinical condition
and effectiveness of treatment. For patients with gout and
volunteers clinical and biochemical studies were performed.
The content of interleukins (IL-1β, IL-17, IL-22, IL-10), tumor
necrosis factor alpha (TNF-α) and VEGF were investigated.
Concentrations of TNF-α, IL-1β and IL-17 characterized of
inflammation intensity at all stages of gout and increased
linearly as the disease progressed. At the stage of asymptomatic hyperuricemia, there were an increased (75% of the
control group) concentration of IL-22 on the background of
lymphopenia, low concentrations of IL-10 and VEGF. This
indicates that the content of IL-22 is a potentially informative biomarker of inflammation intensity as well as a possible
predictor of the development of immune-dependent complications and vascular catastrophes in the early stages of gout
without signs of joint damage. The concentration of TNF-α
positively correlates with the content of IL-10 (r = 0.534); whereas the concentration of IL-1β is independent
of the content of IL-10. The relationship between IL-1β and
VEGF concentrations (r = 0.40) suggests that IL-1β
is more closely associated with endothelial dysfunction and the
risk of vascular complications. IL-22 levels do not correlate
with other cytokine status, but are associated with lymphocyte
counts, so signs of Th22-dependent immune inflammation may
be a potential biomarker of lymphocytic depression status in
gout. Cytokine status changes in different phases and stages
of hyperuricemia. Comparing these changes with the clinical
and laboratory picture improves monitoring of the disease
development and effectiveness of treatment.
Keywords:
stages of gout, inflammation, cytokines, vascular complications.
References
- Amaral FA, Bastos LF, Oliveira TH, et al. Transmembrane FNO-α is sufficient for articular inflammation and hypernociception in a mouse model of gout. Eur J Immunol. 2016;46(1):204-11.
CrossRef
PubMed
- Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010; 12(2):206.
CrossRef
PubMed PubMedCentral
- Maltsev DV, Natrus LV, Kondratiuk VYe, Degtyarova IE. Immunological aspects of pathogenesis of gout in light of recent scientific discoveries as a key for development of informative biomarkers and innovative therapeutic strategies Biol Stud. 2018;12(3-4):103-16.
CrossRef
- Hao G, Duan W, Sun J, Liu J, Peng B. Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, FNO-α and COX-2. Exp Ther Med. 2019;17(1):812-6.
CrossRef
- Webb R, Jeffries M, Sawalha AH. Uric acid directly promotes human T-cell activation. Am J Med Sci. 2009;337(1):23-7.
CrossRef
PubMed
- Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum. 2009;60(1):281-9.
CrossRef
PubMed
- Dang W, Xu D, Xie W, Zhou J. Study on the expressions of NLRP3 gene transcript variants in peripheral blood monocytes of primary gout patients. Clin Rheumatol. 2018;37(9):2547-55.
CrossRef
PubMed
- Cavalcanti NG, Marques CD, Lins E, Pereira MC. Cytokine profile in gout: Inflammation driven by IL-6 and IL-18? Immunol Invest. 2016;45(5):383-95.
CrossRef
PubMed
- Zhang QB, Qing YF, Yin CC, et al. Mice with miR-146a deficiency develop severe gouty arthritis via dysregulation of TRAF 6, IRAK 1 and NALP3 inflammasome. Arthritis Res Ther. 2018;20(1):45.
CrossRef
PubMed PubMedCentral
- Liu-Bryan R. Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome. Immunol Cell Biol. 2010;88(1):20-3.
CrossRef
PubMed PubMedCentral
- Estevez-Garcia IO, Gallegos-Nava S, Vera-Pérez E, et al. Levels of cytokines and microRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach. Arthritis Care Res (Hoboken). 2018;70(12):1814-21.
CrossRef
PubMed
- Conforti-Andreoni C, Spreafico R, Qian HL, et al. Uric acid-driven Th17 differentiation requires inflammasomederived IL-1 and IL-18. J Immunol. 2011;187:5842-50.
CrossRef
PubMed
- Liu Y, Zhao Q, Yin Y, McNutt MA, Zhang T, Cao Y. Serum levels of IL-17 are elevated in patients with acute gouty arthritis. Biochem Biophys Res Commun. 2018;497(3):897-902.
CrossRef
PubMed
- Luo G, Yi T, Zhang G, Guo X, Jiang X. Increased circulating Th22 cells in patients with acute gouty arthritis: A CONSORT-compliant article. Medicine (Baltimore). 2017;96(42):e8329.
CrossRef
PubMed PubMedCentral
- Mills KH, Dungan LS, Jones SA, Harris J. The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol. 2013;93(4):489-97.
CrossRef
PubMed
- Masalova EA. Dynamics of indicators of the immune status and rigidity of the vascular wall in patients with gout during therapy with urisan. [Abstract of dissertation]. Kursk: Kursk State Med Univ; 2011. [Russian].
|